Applications and End Users Driving Demand in the DNA Synthesis Market
Demand in the DNA synthesis market is shaped by what customers do with synthetic DNA once they have it. Polaris Market Research valued the market at USD 4.26 billion in 2025 and projects USD 17.24 billion by 2034, a CAGR of 16.85% from 2026 to 2034, with North America the largest region in 2025. This article looks at the applications and end users behind that demand, and at the partnerships suppliers are forming to serve them.
Diagnostics Lead by Application
By application, the report covers diagnostics, therapeutics, and research and development. Diagnostics led with a 25.6% share in 2025, with subsegments for infectious diseases, cancer and others. Molecular diagnostics is one of the uses the page links to the largest type segment, which held a 68.9% share in 2025 alongside PCR and next-generation sequencing. Laboratories and kit developers working in molecular diagnostics therefore remain a core customer group for DNA suppliers. In research and development, the page lists cloning and gene editing, and drug discovery and development, as subsegments.
Therapeutics Is the Fastest-Growing Application
Therapeutics is expected to grow fastest, at a CAGR of 17.2% from 2026 to 2034, with subsegments of gene therapy, preventive medicine and others. The page ties demand to genetic disorders, noting a World Health Organization estimate that 10 per 1,000 individuals are affected, amounting to 70-80 million people worldwide. Demand from oncology, rare disease and regenerative medicine adds to this. For developers advancing gene therapy programs, dependable access to synthetic DNA is a basic input, and the page's emphasis on biopharma expansion points to demand for gene constructs, antibody libraries and synthetic vaccines.
Vaccines and Synthetic Biology
Vaccines and engineered biology are further drivers. The report cites mRNA vaccine development and infectious disease research, including pandemic preparedness, as sources of demand. It also points to synthetic biology applications such as gene circuits and metabolic pathway design. Organizations planning programs in mRNA vaccine development or synthetic biology applications should treat supplier capability as a strategic consideration, because both areas depend on custom DNA.
End Users and Outsourcing
Pharmaceutical and biotechnology firms were the largest end-user group, with a 56.2% share in 2025. The report expects CROs and CDMOs to record the fastest growth, a point worth noting for suppliers planning their service models and for sponsors weighing outsourcing options. Academic and other users sit within the remaining "others" category.
𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:
https://www.polarismarketresearch.com/industry-analysis/dna-synthesis-market
Constraints That Shape Purchasing
The report lists several restraints that buyers in these applications should keep in view: the high cost of long sequences, error rates that rise with sequence length, regulatory complexity across regions, scalability limitations, and technical complexity with specialized requirements. High R&D costs also appear in the table of contents. For programs in diagnostics and therapeutics alike, these factors make it worth confirming a supplier's capabilities before committing to volumes.
Partnerships and Recent Developments
Recent developments show suppliers aligning with downstream demand. In June 2026, IDT launched end-to-end oncology research workflows integrated with Illumina software. In May 2025, Ginkgo Bioworks and Twist Bioscience extended their partnership to three years, with Ginkgo prepaying for DNA products and Twist acquiring long DNA technology licenses. Such arrangements suggest that supply agreements are becoming more integrated with customer workflows.
Regional Demand Drivers
North America held a 42.4% share in 2025, and the US is projected to grow at a CAGR of 17.1% from 2026 to 2034. Asia Pacific is projected at a CAGR of 17.6%, driven by genomics, molecular diagnostics and vaccines, with India at 17.5%. The page notes that India's biopharma industry grew from USD 10 billion in 2014 to USD 165.7 billion in 2024 and is likely to exceed USD 300 billion by 2030. Europe is described as holding a substantial share in 2025.
Key Players
The report names 15 key players: BIONEER CORPORATION; Camena Bioscience Ltd.; DNA Script SAS; Eton Bioscience, Inc.; Eurofins Scientific SE; GenScript Biotech Corporation; IBA Lifesciences GmbH; Integrated DNA Technologies, Inc.; LGC Biosearch Technologies Limited; Molecular Assemblies, Inc.; Quintara Biosciences, Inc.; Synbio Technologies, Inc.; Thermo Fisher Scientific, Inc.; Touchlight Genetics Ltd.; and Twist Bioscience Corporation. Its Porter's Five Forces ratings are moderate for supplier power, low for the threat of new entrants, moderate for buyer power and for the threat of substitutes, and high for rivalry among existing firms.
Practical Takeaways for B2B Buyers
Buyers should begin by mapping their own application, whether diagnostics, therapeutics or research and development, to a supplier's demonstrated capabilities. Those planning to outsource should compare how suppliers work with contract partners, while developers in fast-moving areas should consider how supply agreements, such as the prepayment and licensing arrangement between Ginkgo Bioworks and Twist Bioscience, can support long-term access to DNA products.
Conclusion
Applications and end users explain where synthetic DNA demand is concentrated. Diagnostics lead today, therapeutics are growing fastest, and pharmaceutical and biotechnology firms remain the largest buyers, while outsourcing partners show the strongest growth. Suppliers and buyers in the DNA synthesis market should align capacity, partnerships and service models with these application and end-user patterns.
More Trending Latest Reports By Polaris Market Research: